3,7-二氮杂双环[3.3.1]-壬烷-3-羧酸叔丁酯 | 227940-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3,7-二氮杂双环[3.3.1]-壬烷-3-羧酸叔丁酯
• 中文别名: 7-叔丁氧羰基-3,7-二氮杂双环[3.3.1]壬烷
• 英文名称: tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
• 英文别名: 3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
• CAS: 227940-72-9
• 化学式: C₁₂H₂₂N₂O₂
• 分子量: 226.319
• InChiKey: ZFVNQMTWYYKBES-UHFFFAOYSA-N

物化性质

• 沸点：
  313.8±35.0 °C(Predicted)
• 密度：
  1.052

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放在室温、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
CAS number: 227940-72-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H22N2O2
Molecular weight: 226.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,7-二氮杂双环[3.3.1]-壬烷-3-羧酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3,7-diazabicyclo{3.3.1}nonane
  参考文献：
  名称：

  Modulation of prion polymerization and toxicity by rationally designed peptidomimetics

  摘要：

  细胞朊病毒蛋白的错误折叠和聚集与一系列神经系统疾病有关，这些疾病通常被称为传染性海绵状脑病。由于有关朊病毒致病自组装机制的信息有限，设计朊病毒抑制剂一直是一项艰巨的任务。在这里，我们探讨了基于双脒的拟肽化合物（BPMs）组合库的抗朊病毒特性，该化合物将氨基酸与疏水侧链和芳香侧链结合在一起。在保持双脒单元不变的情况下，合成了一系列结构多样的 BPM，并对其朊病毒调节特性进行了测试。服用 Leu- 和 Trp-BPMs 可分别延迟和完全抑制人朊病毒蛋白（HuPrP）的淀粉样转化。我们发现，每种BPM都能诱导HuPrP形成独特的低聚物纳米结构，其生物物理特性、细胞毒性和对构象特异性抗体的反应各不相同。研究发现，Leu-BPM 可稳定低聚物，而 Trp-BPM 则可实现瞬时低聚，从而形成无毒的非纤维状聚集体。然而，另一种芳香族残基 Phe 会加速 HuPrP 的聚集过程。通过 MD（分子动力学）模拟获得的分子见解表明，每一种 BPM 都以不同的方式与 HuPrP α2-β2 环上的保守 Tyr 169 残基结合，并影响 α2 和 α3 螺旋的稳定性。我们的研究结果表明，这一类新分子具有连接疏水/芳香残基的化学支架，可有效调节朊病毒的聚集和毒性。

  DOI：

  10.1042/bcj20160737
• 作为产物：
  描述：

  2-甲基-2-丙基7-苄基-9-氧代-3,7-二氮杂双环[3.3.1]壬烷-3-羧酸酯 在 10percent Pd/C 氢气 、 sodium cyanoborohydride 、 对甲苯磺酸 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.17h， 生成 3,7-二氮杂双环[3.3.1]-壬烷-3-羧酸叔丁酯
  参考文献：
  名称：

  手性亚磷酰胺配体的固相开发，用于对映选择性共轭加成反应。

  摘要：

  描述了优化手性配体的方法的开发，该手性配体用于空间选择性控制锌烷基向烯酮的对映选择性的铜催化的共轭加成。该方法基于组合原理和固相技术。它包括在固相上包含亚磷酰胺基团的手性联二吡啶衍生的配体的组合合成，以及在将ZnEt2共轭添加到环己烯酮中作为固定反应的固定化研究。最佳识别的配体也分别合成，并以其可溶形式进行研究。聚合物结合的配体获得的结果正确反映了可溶性配体的性能。该库包含的成员给出的ee值在3％到67％之间。“位置扫描” 事实证明该方法对配体系统的研究无效，表明通常应谨慎使用该方法。综上所述，该方法允许快速和有效地优化配体，并导致与聚合物结合的配体的第一对映选择性，Cu催化的共轭加成反应的发展。

  DOI：

  10.1002/1521-3765(20021018)8:20<4767::aid-chem4767>3.0.co;2-o

文献信息

• [EN] (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES<br/>[FR] (DIHYDRO)PYRROLO[2,1-?]ISOQUINOLINES
  申请人：ORGANON NV

  公开号：WO2009098283A1

  公开（公告）日：2009-08-13

  The invention relates to 5,6 - dihydropyrrolo [2,1-a] isoquinoline and pyrrolo[2,1-a] isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.

  这项发明涉及根据通式（I）制备的5,6-二氢吡咯并[2,1-a]异喹啉和吡咯并[2,1-a]异喹啉衍生物，或其药学上可接受的盐。这些化合物可用于治疗不孕症。
• [EN] ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS<br/>[FR] ANALOGUES D'ATAZANAVIR (ATV) POUR TRAITER DES INFECTIONS PAR LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2018145021A1

  公开（公告）日：2018-08-09

  The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, the compound of formula (I) for use in therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I. Preferred compounds are N-[(2S) -1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino) -3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(phenyl) methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate atazanavir (ATV) analogues substituted by several heterocycles, such as e.g. pyrazole (Rl); e.g. oxetane (substituent of X2); e.g. pyridine or pyrimidine (X1); e.g. piperazine or 3,8-diazabicyclo[3.2.1]octan (X2).

  该发明提供了一种如下式的化合物：或其药学上可接受的盐。该发明还提供了包含如下式化合物的药物组合物，制备如下式化合物的方法，以及利用如下式化合物治疗HIV病毒增殖、治疗艾滋病或延缓哺乳动物艾滋病症状发作的治疗方法中使用的如下式化合物。首选化合物是N-[(2S)-1-[2-[(2S,3S)-2-羟基-3-[[(2S)-2-(甲氧羰基氨基)-3,3-二甲基丁酰]氨基]-4-苯基丁基]-2-[(苯基)甲基]肼基]-3,3-二甲基-1-氧丁酸-2-基]氨基甲酸酯阿扎那韦（ATV）类似物，其被若干杂环取代，例如吡唑（R1）；例如氧杂环（X2的取代基）；例如吡啶或嘧啶（X1）；例如哌嗪或3,8-二氮杂双环[3.2.1]辛烷（X2）。
• [EN] NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES<br/>[FR] AMIDES DE DIAZABICYCLOALCANES SÉLECTIVES D'UN SOUS-TYPE DE RÉCEPTEUR D'ACÉTYLCHOLINE NICOTINIQUE
  申请人：TARGACEPT INC

  公开号：WO2009111550A1

  公开（公告）日：2009-09-11

  The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

  本发明涉及结合并调节神经元尼古丁型乙酰胆碱受体活性的以下式(I)化合物，以及制备这些化合物的方法，含有这些化合物的药物组合物，以及利用这些化合物治疗各种疾病和疾病的方法，包括与中枢神经系统（CNS）功能障碍相关的疾病。
• Bispidine antiarrhythmic compounds
  申请人：AstraZeneca AB

  公开号：US06291475B1

  公开（公告）日：2001-09-18

  There is provided a compound of formula I, wherein R1, R2, R9, R10, R11, R12, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

  提供了一个式I的化合物， 其中R1、R2、R9、R10、R11、R12、X、A和B的含义如描述中所给，这些化合物在心律失常的预防和治疗中特别有用，尤其是房颤和室颤。
• Asymmetric Direct Aldol Reaction of Functionalized Ketones Catalyzed by Amine Organocatalysts Based on Bispidine
  作者：Jie Liu、Zhigang Yang、Zhen Wang、Fei Wang、Xiaohong Chen、Xiaohua Liu、Xiaoming Feng、Zhishan Su、Changwei Hu

  DOI：10.1021/ja800839w

  日期：2008.4.1

  Organocatalysts containing primary-secondary amine based on bispidine and amino acid have been designed to catalyze the asymmetric direct aldol reaction of functionalized ketones including alpha-keto phosphonates, alpha-keto esters, as well as alpha,alpha-dialkoxy ketones as aldol reaction acceptors. The corresponding products with chiral tertiary alcohols were obtained in moderate to high yields (up

  含有基于双吡啶和氨基酸的伯仲胺的有机催化剂已被设计用于催化功能化酮的不对称直接醛醇反应，包括 α-酮膦酸酯、α-酮酯以及作为醛醇反应受体的 α,α-二烷氧基酮。以中等至高产率（高达 97%）和高对映选择性（高达 98% ee）获得具有手性叔醇的相应产物。过渡结构的理论研究表明，质子化哌啶对该反应的反应性和对映选择性很重要。